GlassScriptPhysician profile
Virginia Fischer
NPI 1689071060
$2,599.57
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $401 · 2023: $1,085 · 2024: $991 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Long Term Medical Supply Or Device Loan: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.64 |
| Long Term Medical Supply Or Device Loan | $549.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $549.09 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $430.31 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $288.92 | 2022-2024 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.30 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $209.37 | 2023-2024 | Auvelity, Sunosi |
| Abbvie INC. | $200.55 | 2022-2025 | |
| Biogen, INC. | $173.43 | 2023 | |
| Indivior INC. | $108.03 | 2024-2025 | Sublocade |
| Boston Scientific Corporation | $98.13 | 2023 | |
| Ironshore Pharmaceuticals INC. | $52.21 | 2024 | |
| Alkermes, INC. | $44.48 | 2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $30.13 | 2024 | Fanapt |
| Sage Therapeutics, LLC | $27.69 | 2023 | |
| Tempus Ai, INC | $27.53 | 2024 | |
| Neurocrine Biosciences, INC. | $22.44 | 2023 | Ingrezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.44 | 2023 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $19.79 | 2024 | Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $19.38 | 2024 | Cobenfy |
| Lundbeck LLC | $19.10 | 2024 | Rexulti |
| Braeburn INC. | $18.31 | 2023 | Brixadi |
| Idorsia Pharmaceuticals US INC | $14.94 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.